We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT05039710
Previous Study | Return to List | Next Study

A Study of JNJ-75220795 in Japanese Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05039710
Recruitment Status : Recruiting
First Posted : September 9, 2021
Last Update Posted : November 9, 2022
Sponsor:
Information provided by (Responsible Party):
Janssen Pharmaceutical K.K.

Brief Summary:
The purpose of this study is to assess the safety and tolerability of single subcutaneous (SC) dose of JNJ-75220795 in Japanese participants.

Condition or disease Intervention/treatment Phase
Fatty Liver Drug: JNJ-75220795 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 in Japanese Participants
Actual Study Start Date : November 8, 2021
Estimated Primary Completion Date : November 28, 2022
Estimated Study Completion Date : June 22, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort 1: JNJ-75220795 or Placebo
Participants will receive single subcutaneous (SC) dose of JNJ-75220795 Dose 1 or matching placebo on Day 1 in Cohort 1.
Drug: JNJ-75220795
JNJ-75220795 will be administered as SC injection.

Other: Placebo
Matching placebo will be administered as SC injection.

Experimental: Cohort 2: JNJ-75220795 or Placebo
Participants will receive single SC dose of JNJ-75220795 Dose 2 or matching placebo on Day 1 in Cohort 2.
Drug: JNJ-75220795
JNJ-75220795 will be administered as SC injection.

Other: Placebo
Matching placebo will be administered as SC injection.




Primary Outcome Measures :
  1. Number of Participants with Treatment-emergent Signs and Symptoms/Adverse Events (AEs) [ Time Frame: Up to Day 168 ]
    Number of participants with treatment-emergent signs and symptoms/adverse events (including allergic reactions/hypersensitivity and local injection site reactions) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Treatment-emergent adverse events (TEAEs) are defined as AEs with onset or worsening on or after date of first dose of study treatment.

  2. Number of Participants With Change From Baseline in Vital Signs Abnormalities [ Time Frame: Baseline, Up to Day 168 ]
    Number of participants with change from baseline in vital signs abnormalities including body temperature (axillary), pulse, respiratory rate and blood pressure will be reported.

  3. Number of Participants With Change From Baseline in Clinical Laboratory Abnormalities [ Time Frame: Baseline, Up to Day 168 ]
    Number of participants with change from baseline in clinical laboratory abnormalities including hematology, serum chemistry and urinalysis will be reported.

  4. Number of Participants With Change From Baseline in Physical Examination Abnormalities [ Time Frame: Baseline, Up to Day 168 ]
    Number of participants with change from baseline in physical examination abnormalities will be reported.

  5. Number of Participants With Change From Baseline in Electrocardiogram (ECG) Abnormalities [ Time Frame: Baseline, Up to Day 168 ]
    Number of participants with change from baseline in ECG abnormalities will be reported.


Secondary Outcome Measures :
  1. Percent Change in Liver Fat Content Measured by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) [ Time Frame: From Baseline to Weeks 6, 12, 18, and 24 ]
    Percent change in liver fat content as measured by MRI-PDFF will be reported.

  2. Maximum Observed Plasma Concentration (Cmax) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]
    Cmax of JNJ-75220795 will be reported.

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]
    Tmax of JNJ-75220795 will be reported.

  4. Apparent Elimination Half-Life (t1/2) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]
    t1/2 is defined as apparent elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve.

  5. Area Under the Plasma Concentration Time Curve of JNJ-75220795 from Time Zero to Infinite time (AUC [0-Infinity]) [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]
    AUC (0-Infinity) is defined as the area under the plasma concentration versus time curve of JNJ-75220795 from time zero to infinite time.

  6. Area Under the Plasma Concentration versus Time Curve of JNJ-75220795 from Time Zero to Time of the Last Measurable Concentration (AUC [0-Last]) [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]
    AUC (0-Last) is defined as area under the plasma concentration versus time curve of JNJ-75220795 from time zero to time of the last measurable concentration.

  7. Total Apparent Clearance (CL/F) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]
    CL/F is defined as total apparent clearance of JNJ-75220795.

  8. Apparent Volume of Distribution (Vd/F) of JNJ-75220795 [ Time Frame: Predose up to 48 hours postdose (up to Day 3) ]
    Vd/F is defined as apparent volume of distribution of JNJ-75220795.

  9. Number of Participants with Treatment Emergent Anti-drug Antibody (ADA) [ Time Frame: Up to Day 168 ]
    Number of participants with treatment emergent ADA will be reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants with certain genetic predispositions to non-alcoholic fatty liver disease (NAFLD) determined at screening
  • Presence of liver steatosis at screening
  • Participants on anti-hypertensive and/or lipid lowering medications and/or glucose lowering medications must be on stable dose(s) for at least 4 weeks prior to screening
  • Body mass index between 18 kilograms per meter square (kg/m^2) and 40 kg/m^2 inclusive, and body weight stable defined as no more than 5 percent (%) body weight loss or gain within 3 months prior to screening (based on participant's report) and no more than 5% body weight loss or gain from screening to randomization

Exclusion Criteria:

  • Known allergies, hypersensitivity, or intolerance to excipients
  • History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HbsAg or anti-HCV at screening. And/or history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV or syphilis at screening
  • Participants with clinical or biochemical (international normalized ratio [INR] greater than [>] 1.2, or platelet count less than [<] lower limits of normal [LLN]) evidence of hepatic decompensation at screening or baseline
  • Estimated glomerular filtration rate (eGFR) by Japanese eGFR formula below 60 milliliters per minute [mL/min] at screening
  • Thyroid stimulating hormone (TSH) levels, free triiodothyronine (FT3) and free thyroxine (FT4) outside normal limits of the clinical laboratory's reference range at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05039710


Contacts
Layout table for location contacts
Contact: Study Contact 844-434-4210 Participate-In-This-Study@its.jnj.com

Locations
Layout table for location information
Japan
Souseikai Fukuoka Mirai Hospital Recruiting
Fukuoka-shi, Japan, 813-0017
Corporation Heishinkai ToCROM Clinic Recruiting
Shinjuku-ku, Japan, 160-0008
Corporation Heishinkai OCROM Clinic Recruiting
Suita-city, Japan, 565-0853
Sumida Hospital Recruiting
Tokyo, Japan, 130-0004
Sponsors and Collaborators
Janssen Pharmaceutical K.K.
Investigators
Layout table for investigator information
Study Director: Janssen Pharmaceutical K.K., Japan Clinical Trial Janssen Pharmaceutical K.K.
Layout table for additonal information
Responsible Party: Janssen Pharmaceutical K.K.
ClinicalTrials.gov Identifier: NCT05039710    
Other Study ID Numbers: CR109081
75220795NAS1002 ( Other Identifier: Janssen Pharmaceutical K.K., Japan )
First Posted: September 9, 2021    Key Record Dates
Last Update Posted: November 9, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
URL: https://www.janssen.com/clinical-trials/transparency

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Liver Diseases
Digestive System Diseases